Jazz Pharmaceuticals (JAZZ) Financials: Revenue & Earnings
JAZZ$208.67+3.61 +1.76%
$13.55B
Market Cap
13.49
P/E
8.49
Forward P/E
60
Score
Jazz Pharmaceuticals (JAZZ) Financials: Revenue & Earnings
JAZZ price $208.67 +3.61 +1.76%
- Ticker
- JAZZ
- Price
- $208.67
- Change
- +3.61 +1.76%
- Market cap ?
- $13.55B
- P/E ?
- 13.49
- Forward P/E ?
- 8.49
- Dividend yield ?
- 0.00%
- Beta ?
- 0.32
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 60
- Value
- 66
- Quality
- 60
- Growth
- 54
Stocklytics score rationale: value 66, quality 60, growth 54.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 1487973000 | 1618693000 | 1890922000 | 2161761000 | 2363567000 | 3094238000 | 3659374000 | 3834204000 | 4068950000 | 4267586000 |
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the…
Earnings and financials
Jazz Pharmaceuticals plc (JAZZ) trades at $208.67, with a market cap of $13.55B and a trailing P/E of 13.49. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 1487973000 | 1618693000 | 1890922000 | 2161761000 | 2363567000 | 3094238000 | 3659374000 | 3834204000 | 4068950000 | 4267586000 |
Insights · Dividends · Forecast · Financials · Learn